Beijing Biostar Pharmaceuticals Valuation
Is 2563 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2563 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2563's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2563's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2563?
Key metric: As 2563 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 2563's PB Ratio? | |
|---|---|
| PB Ratio | 13.5x |
| Book | CN¥723.16m |
| Market Cap | CN¥9.79b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 139.3x |
| Enterprise Value/EBITDA | -44.8x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 2563's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.5x | ||
2162 Keymed Biosciences | 3.9x | 16.0% | HK$11.1b |
2696 Shanghai Henlius Biotech | 4.3x | 7.3% | HK$11.8b |
6826 Shanghai Haohai Biological Technology | 1.1x | 16.8% | HK$14.2b |
1530 3SBio | 0.9x | 14.6% | HK$13.5b |
2563 Beijing Biostar Pharmaceuticals | 13.5x | n/a | HK$10.5b |
Price-To-Book vs Peers: 2563 is expensive based on its Price-To-Book Ratio (13.5x) compared to the peer average (2.5x).
Price to Book Ratio vs Industry
How does 2563's PB Ratio compare vs other companies in the HK Biotechs Industry?
| 4 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
2137 Brii Biosciences | 0.2x | -7.4% | US$93.02m |
2126 JW (Cayman) Therapeutics | 0.3x | -1.8% | US$69.67m |
1244 3D Medicines | 0.5x | n/a | US$57.31m |
6628 Transcenta Holding | 0.3x | 12.7% | US$33.30m |
| 4 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: 2563 is expensive based on its Price-To-Book Ratio (13.5x) compared to the Hong Kong Biotechs industry average (2.2x).
Price to Book Ratio vs Fair Ratio
What is 2563's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 13.5x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 2563's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
China Shineway Pharmaceutical Group
HK$6.6b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.76
7D
5.8%
1Y
n/a
3SBio
HK$13.5b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$5.72
7D
-2.2%
1Y
-22.2%
JW (Cayman) Therapeutics
HK$538.1m
A clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China.
2126
HK$1.34
7D
-1.5%
1Y
-58.9%